ducovest

BHC:CA:TSX-Bausch Health Companies Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

CAD 11.42

Change

-0.20 (-1.72)%

Market Cap

CAD 3.94B

Volume

0.21M

Analyst Target

CAD 23.55
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Currency: CAD

Country : Canada

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
TLRY:CA Tilray Inc

N/A

 CAD 1.89B
CURA:CA Curaleaf Holdings Inc.

N/A

 CAD 1.61B
CRON:CA Cronos Group Inc

N/A

 CAD 1.07B
DHT-UN:CA DRI Healthcare Trust

N/A

 CAD 0.75B
WEED:CA Canopy Growth Corp

N/A

 CAD 0.60B
AOV:CA Amotiv Limited

N/A

 CAD 0.58B
GUD:CA Knight Therapeutics Inc.

N/A

 CAD 0.58B
DHT-U:CA DRI Healthcare Trust

N/A

 CAD 0.54B
CPH:CA Cipher Pharmaceuticals Inc

N/A

 CAD 0.38B
ACB:CA Aurora Cannabis Inc

N/A

 CAD 0.36B

ETFs Containing BHC:CA

DFEN Direxion Daily Aerospace .. 10.52 % 1.09 %

N/A

 USD 0.17B
PPA Invesco Aerospace & Defen.. 8.18 % 0.59 %

N/A

 USD 4.55B
HHL:CA Harvest Healthcare Leader.. 5.21 % 1.15 %

N/A

 N/A
XAR SPDR® S&P Aerospace & De.. 4.65 % 0.35 %

N/A

 USD 2.91B
PFF iShares Preferred and Inc.. 4.17 % 0.46 %

N/A

 N/A
EDOW First Trust Dow 30 Equal .. 3.64 % 0.50 %

N/A

 USD 0.23B
XLI Industrial Select Sector .. 3.24 % 0.13 %

N/A

 USD 20.88B
MOAT VanEck Morningstar Wide M.. 2.77 % 0.49 %

N/A

 N/A
DUSL Direxion Daily Industrial.. 2.61 % 1.05 %

N/A

 USD 0.04B
UXI ProShares Ultra Industria.. 2.15 % 0.95 %

N/A

 N/A
RGI Invesco S&P 500® Equal W.. 1.45 % 0.40 %

N/A

 N/A
OEW 1.25 % 0.40 %

N/A

 N/A
NHYB:CA NBI High Yield Bond ETF 0.89 % 0.00 %

N/A

 CAD 1.07B
RSP Invesco S&P 500® Equal W.. 0.22 % 0.20 %

N/A

 N/A
CJNK 0.00 % 0.30 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.72% 6% D- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.72% 6% D- 4% F
Trailing 12 Months  
Capital Gain 9.70% 75% C 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.70% 75% C 36% F
Trailing 5 Years  
Capital Gain -70.11% 57% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.11% 57% F 6% D-
Average Annual (5 Year Horizon)  
Capital Gain -5.50% 50% F 8% B-
Dividend Return -5.50% 50% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.66% 45% F 19% F
Risk Adjusted Return -11.79% 50% F 16% F
Market Capitalization 3.94B 100% F 83% B

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector